Futura Medical PLC (AIM:FUM, OTC:FAMDF) has received a boost from its blue-chip partner Haleon PLC (LSE:HLN, NYSE:HLN) on the timing of the US roll-out of Eroxon, Futura's fast-acting gel for erectile dysfunction.
In its results statement earlier Thursday, the consumer products giant said Eroxon would be available Stateside before the year-end.
Futura pointed out that current market expectations do not include any contribution from the US launch in the current financial year.
It told investors that trading has been in line with market expectations.
Eroxon is the first US Food & Drug Administration-approved topical erectile dysfunction treatment for sale over-the-counter.
Haleon, in its announcement, said:" We continue to get ready for the launch and believe that this product addresses a significant unmet consumer need and expect the product to be available in-market before the end of this year."